| HOME >> MEDICINE >> TECHNOLOGY |
-- Treatment arm A received dose-dense combination of doxorubicin and
cyclophosphamide with Avastin, followed by paclitaxel and Avastin,
followed by Avastin alone. Avastin was given every 2 weeks at a dose
of 10 mg/kg for 1 year.
-- Treatment arm B was only different to arm A in that Avastin was
introduced after completion of doxorubicin therapy in conjunction with
paclitaxel. As with arm A, patients remained on Avastin for 1 year
after Avastin initiation.
The primary objective of the study was to determine the incidence of
clinically apparent cardiac dysfunction in patients with lymph node
positive breast cancer treated with bevacizumab and dose dense
doxorubicin/cyclophosphamide followed by paclitaxel (ddAC>T). Patients were
evaluated clinically and with serial assessments of left ventricular
function over the course of their treatment and for six months following
treatment.
Additional information
-- Roche in Oncology:
http://www.roche.com/pages/downloads/company/pdf/mboncology05e_b.pdf
-- Roche Health Kiosk, Cancer:
http://www.health-kiosk.ch/start_krebs
References:
(1) Miller KD, et al. E2100 Breast Cancer Res Treat 2005;94:S6
(Abstract 3)
(2) Kamangar F, et al. J Clin Oncol 2006; 24(14): 2137-50.
| SOURCE Roche Copyright©2007 PR Newswire. All rights reserved |